Home > Cardiology > ACC/WCC 2020 > Genetics and Prevention > Evinacumab significantly reduces LDL-C in homozygous FH patients

Evinacumab significantly reduces LDL-C in homozygous FH patients

Presented By
Dr F. Raal, University of the Witwatersrand, South Africa
ACC 2020
Results from a phase 3 trial demonstrated that evinacumab substantially lowered low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (FH), regardless of LDL receptor function. The PCSK9 inhibitor evinacumab may provide an effective treatment option for patients with homozygous FH who are unable to reach target LDL-C despite multiple conventional lipid lowering therapies with or without apheresis. Dr Frederick Raal (University of the Witwatersrand, South Africa), who presented the results of this study, explained that evinacumab is a fully human monoclonal antibody inhibitor of ANGPTL3 and reduces LDL-C regardless of the LDL receptor [1]. Patients were eligible if they were 12 years or older and on a stable maximally tolerated lipid-lowerin...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on